Peptides · Peptide comparison
Cartalax vs Ventfort
Chondroprotective tripeptide bioregulator (Ala-Glu-Asp) that activates chondrogenic differentiation through SOX9/COL2A1/aggrecan upregulation, reverses senescence-associated secretory phenotype in aging chondrocytes, and provides geroprotective effects through SIRT-6 upregulation and p16/p21/p53 suppression
Vascular peptide bioregulator complex derived from bovine aorta containing ultrashort peptides (including KED sequence) that normalize vascular endothelial function, reduce total cholesterol by up to 30% in clinical studies, and restore arterial elasticity through epigenetic regulation of extracellular matrix remodeling genes in aging blood vessels
- Anti-Aging
- Anti-Aging
At a glance
Quick comparison
Efficacy
Benefit ratings
Anti-Aging
Healing & Recovery
Hormone Support
Blood Vessel Health
Cholesterol Support
Heart Protection
Technical data
Compound specifications
Cartalax
- Molecular formula
- C12H19N3O8
- Molecular weight
- 333.3 g/mol
- Half-life
- Short plasma half-life typical of tripeptides (minutes to hours); biological effects persist for weeks to months through epigenetic gene regulation; metabolized to constituent amino acids
- Bioavailability
- Orally bioavailable via intestinal peptide transporters (PepT1/PepT2, LAT1); 10-fold more potent than crude cartilage polypeptide complex at chondrogenic activation (200 vs 2000 ng/mL effective concentration)
- CAS number
- Not yet registered (research compound)
Ventfort
- Molecular formula
- Complex peptide mixture (multiple sequences, MW range up to 5 kDa; active component KED: C13H22N4O7)
- Molecular weight
- Complex mixture up to 5,000 Da; KED active tripeptide: ~362.3 g/mol
- Half-life
- Short plasma half-life typical of ultrashort peptides (minutes to hours); biological effects persist for weeks to months through epigenetic modifications to vascular gene expression; metabolized to constituent amino acids
- Bioavailability
- Oral formulation absorbed via intestinal peptide transporters; ultrashort peptides in the complex have efficient cellular uptake; injectable form provides direct systemic delivery; tissue-derived peptides maintain bioactivity through enteric-coated capsule formulation
- CAS number
- Not applicable (tissue-derived complex)
Protocols
Dosing compared
Cartalax
Subcutaneous
- 200 mcgOnce daily · 10-day cycles, repeated periodicallyCartalax has only lab and cell-culture research, so there is no trial-set human dose. In practice it is commonly given as 200 mcg daily in short 10-day cycles, matching how other Khavinson short peptides are used [3][4].
Ventfort
Oral administration
- 1 capsule (10 mg) once dailyOnce daily before meals · 10-day initial courseKhavinson A-3 vascular bioregulator (Ventfort); each capsule contains 10 mg peptide complex from vascular tissue [6]. Dietary-supplement form; research/wellness use.
- 2 capsules (20 mg) dailyOnce or twice daily before meals · 10–20 day courseStandard daily dose (20 mg/day); courses typically repeated every 6 months [6]. Sublingual enteric-coated capsules used for buccal absorption.
Subcutaneous injection
- 5–10 mgOnce daily · 10–20 day courseInjectable form of the A-3 complex for direct systemic delivery; same course length as oral [6]. Research use only.
Applications
Best suited for
Cartalax
- Cartilage regeneration and protection in age-related osteoarthritis
- Cartalax is particularly well-suited for individuals focused on cartilage regeneration and protection in age-related osteoarthritis. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
- Connective tissue repair and maintenance in aging individuals
- Cartalax is particularly well-suited for individuals focused on connective tissue repair and maintenance in aging individuals. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
- Geroprotective therapy targeting the SIRT-6/senescence axis in musculoskeletal tissue
- Cartalax is particularly well-suited for individuals focused on geroprotective therapy targeting the sirt-6/senescence axis in musculoskeletal tissue. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
- Complementing conventional osteoarthritis treatments with bioregulatory peptide therapy
- Cartalax is particularly well-suited for individuals focused on complementing conventional osteoarthritis treatments with bioregulatory peptide therapy. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Ventfort
- Cardiovascular geroprotection — preserving vascular function during aging
- Ventfort is particularly well-suited for individuals focused on cardiovascular geroprotection — preserving vascular function during aging. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
- Age-related arterial stiffness and endothelial dysfunction
- Ventfort is particularly well-suited for individuals focused on age-related arterial stiffness and endothelial dysfunction. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
- Lipid profile optimization as adjunctive support alongside lifestyle modifications
- Ventfort is particularly well-suited for individuals focused on lipid profile optimization as adjunctive support alongside lifestyle modifications. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
- Comprehensive Khavinson bioregulator protocols targeting cardiovascular health
- Ventfort is particularly well-suited for individuals focused on comprehensive khavinson bioregulator protocols targeting cardiovascular health. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Safety profile
Side effects
Cartalax
Common
- Mild injection site reaction
- Mild GI discomfort
- Mild fatigue
- Transient joint stiffness
Uncommon
- Temporary increase in joint discomfort
Serious
- No documented serious adverse effects
Ventfort
Common
- Injection site reaction
- Mild fatigue
- Mild headache
- Mild blood pressure fluctuation
Uncommon
- Mild dizziness
Serious
- No documented serious adverse effects
Research status
Safety & evidence
Cartalax
- Evidence level
- Moderate human trials (Phase 1-2)
- FDA status
- Research compound
- Safety overview
- Cartalax (polypeptide complex from bovine cartilage) has not undergone formal FDA approval or rigorous clinical safety trials. The safety profile is based on traditional use in Russia and Eastern Europe as a cartilage extract supplement, with limited published safety data. As a complex mixture of polypeptides, collagens, and proteoglycans, the actual active components and their pharmacology are undefined, making toxicity prediction impossible. Potential allergic reactions to bovine proteins exist, and contamination risks from source animal tissues cannot be ruled out without pharmaceutical manufacturing standards.
Contraindications
- Known hypersensitivity to peptide bioregulators or constituent amino acids (alanine, glutamic acid, aspartic acid)
- Pregnancy and breastfeeding — insufficient reproductive safety data
- Active joint infection — treat infection before initiating peptide bioregulator therapy
- Malignant bone or cartilage tumors — proliferative effects of peptide bioregulators may be contraindicated
Ventfort
- Evidence level
- Limited human trials
- FDA status
- Research compound
- Safety overview
- Ventfort (collagen peptide complex) demonstrates excellent safety profile from cosmetic and nutritional supplement use spanning decades. Hydrolyzed collagen peptides pass through the GI tract largely unchanged—minimal systemic absorption occurs, making serious adverse effects unlikely. Mild gastrointestinal side effects (bloating, dyspepsia) occur in <5% of users and are generally self-limiting. Allergic reactions are rare given the high molecular weight peptide fragments; histamine content is negligible in properly processed formulations.
Contraindications
- Known hypersensitivity to bovine-derived peptide products or any constituent amino acids
- Active bleeding disorders or concurrent anticoagulant therapy without medical supervision
- Severe cardiovascular disease requiring immediate medical intervention
- Pregnancy and breastfeeding — insufficient reproductive safety data
Decision guide
Which is right for you?
Cartalax
Choose Cartalax if…
- Cartilage regeneration and protection in age-related osteoarthritis
- Connective tissue repair and maintenance in aging individuals
- Geroprotective therapy targeting the SIRT-6/senescence axis in musculoskeletal tissue
- Complementing conventional osteoarthritis treatments with bioregulatory peptide therapy
Ventfort
Choose Ventfort if…
- Cardiovascular geroprotection — preserving vascular function during aging
- Age-related arterial stiffness and endothelial dysfunction
- Lipid profile optimization as adjunctive support alongside lifestyle modifications
- Comprehensive Khavinson bioregulator protocols targeting cardiovascular health